-
Mashup Score: 0Phase 2 TROPiCS-03 Study Shows Sacituzumab Govitecan Has ‘Promising Efficacy’ for ES-SCLC | Docwire News - 4 month(s) ago
Sacituzumab govitecan “demonstrated promising efficacy” as a second-line therapy for extensive-stage small cell lung cancer (ES-SCLC), regardless of platinum sensitivity.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Key Research Takeaways on Patient Selection in Sublobar Resection for Early-Stage NSCLC | Docwire News - 4 month(s) ago
Robert E. Merritt, MD, MBA, FACS, discusses the importance of patient selection and adhering to oncologic principles when utilizing sublobar resection to treat early-stage NSCLC.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
💡 Tune in for the second segment of our interview with Robert Merritt, MD, MBA, of @OSUCCC_James, as he dives into the importance of oncologic principles and other key considerations surrounding sublobar resection in NSCLC. ➡️ Watch: https://t.co/sj8QqzTQNv #NSCLC https://t.co/eTXZPozcjg
-
-
Mashup Score: 02025 Cancer Statistics Report: Lung Cancer Remains Leading Cause of Cancer Mortality in US | Docwire News - 4 month(s) ago
Although lung cancer incidence is declining and five-year survival rates are increasing, lung cancer remains the top cause of cancer mortality in the United States.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 What does the 2025 Cancer Statistics report from @AmericanCancer show about lung cancer? ➡️ Find the key details and data on lung cancer here: https://t.co/AbutvkBiOe #lcsm #NSCLC #SCLC #LungCancer https://t.co/XMCkxTnkQf
-
-
Mashup Score: 0How Socioeconomic Factors Impact Surgical Care for US Veterans With Early-Stage NSCLC | Docwire News - 4 month(s) ago
Though veterans with high socioeconomic deprivation experience less than optimal surgical care, they do not experience inferior long-term outcomes after surgery for NSCLC.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 How do socioeconomic factors affect care and surgical outcomes for veterans with NSCLC? 📰 A new study by a team from @WUSTL provided insights and key action items. ➡️ Learn more: https://t.co/DToVHr1vQZ #lcsm #LungCancer #NSCLC https://t.co/1Xzs3rWi5X
-
-
Mashup Score: 0
ALK Positive has established a 12-member scientific advisory board that will guide the patient-driven organization’s research and strategic priorities, its leadership announced.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
⭐ Today, @ALKPositiveinc announced the formation of its Scientific Advisory Board! 🗨️ Don't miss this insightful interview about the new board with ALK Positive President Kirk Smith & Dr. Ken Culver, Director of Research & Clinical Affairs! ➡️ Watch: https://t.co/FV3wWGEKnh https://t.co/ej0pyLOEkY
-
-
Mashup Score: 7The Future of Surgery for Stage IV Lung Cancer: Dr. Antonoff Shares Hopes, Insights | Docwire News - 4 month(s) ago
Mara B. Antonoff, MD, FACS, of the University of Texas MD Anderson Cancer Center, discusses what could be on the horizon for surgery in stage IV lung cancer at STS 2025.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 What does the future hold for surgery in stage IV lung cancer? 💡 In this new interview, @maraantonoff discusses what she hopes to see on the horizon and shares insights from the #STS2025 session on the topic. ➡️ Watch: https://t.co/YWwRCJ9iXP @STS_CTsurgery #lcsm #STS25 https://t.co/sjYQlYEBb0
-
-
Mashup Score: 0Phase 3 HARMONi-6/AK112-306 Trial of Ivonescimab Plus Chemotherapy for NSCLC Completes Enrollment | Docwire News - 4 month(s) ago
The trial is comparing ivonescimab plus platinum-based chemotherapy to tislelizumab plus platinum-based chemotherapy as first-line therapy for squamous non–small cell lung cancer.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 Patient enrollment has been completed in the phase 3 HARMONi-6/AK112-306 trial, according to an announcement from Akeso Biopharma. ➡️ Learn more about the study: https://t.co/243df3VyHx #NSCLC #lcsm https://t.co/1QaOjt16JU
-
-
Mashup Score: 2Deep Learning Approach Characterizes Tumor Microenvironment in NSCLC | Docwire News - 4 month(s) ago
HistoTME, a novel deep learning approach, can characterize the tumor microenvironment molecular composition and predict responses to immune checkpoint inhibitors in NSCLC.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 A novel deep learning approach may be an effective way to characterize the TME & predict responses to ICIs in NSCLC, according to research presented at #SITC24 by a team from @theNCI. ➡️ Learn more: https://t.co/LqNptHvtKG #lcsm #LungCancer #NSCLC https://t.co/GFHInDwBXM
-
-
Mashup Score: 3Stephen Liu, MD, Discusses the COCOON Trial | Docwire News - 4 month(s) ago
Stephen V. Liu, MD, discusses the randomized phase 2 COCOON trial, which is evaluating a prophylactic dermatologic regimen with amivantamab plus lazertinib in NSCLC.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
⭐ @StephenVLiu of @Georgetown, @LombardiCancer joined us to discuss the announcement that the COCOON trial met its primary endpoint and share his insights on the prophylactic dermatological regimen & key remaining questions. ➡️ Watch: https://t.co/iVTT93H0Na #NSCLC #lcsm https://t.co/veF8Ex5kAT
-
-
Mashup Score: 7Real-World Study: Lobectomy Linked With Higher OS Rates Than Wedge Resection in Early-Stage NSCLC | Docwire News - 4 month(s) ago
Lobectomy is associated with improved long-term survival compared with wedge resection for patients with stage 1A non-small cell lung cancer, according to a STS 2025 presentation.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 Lobectomy is associated with improved long-term survival compared with wedge resection for early-stage NSCLC, according to research presented by Christopher Seder, MD, of @RushMedical at #STS2025. ➡️ Read more: https://t.co/bb4RiX8eDu #NSCLC #LungCancer @STS_CTsurgery https://t.co/woFFnR4xYo
-
📋 Sacituzumab govitecan “demonstrated promising efficacy” as a second-line therapy for ES-SCLC, according to TROPiCS-03 data published in @JTOonline by Afshin Dowlati, MD, of @caseccc, @UHHospitals, and colleagues. ➡️ Learn more: https://t.co/kZVTZAcQvh #SCLC #lcsm https://t.co/lCvuDwoiIz